News stories about Zynerba Pharmaceuticals (NASDAQ:ZYNE) have trended somewhat positive recently, according to Accern. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Zynerba Pharmaceuticals earned a news impact score of 0.16 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.0221844740755 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media stories that may have impacted Accern’s analysis:
- Zynerba Pharmaceuticals initiates Phase 2 trial of ZYN002 in DEE (seekingalpha.com)
- Oppenheimer Downgrades Zynerba Pharmaceuticals (ZYNE) to Market Perform (americanbankingnews.com)
- BRIEF-Zynerba Pharmaceuticals Initiates Open Label Phase 2 Trial Of ZYN002 In Developmental And Epileptic Encephalopathies (DEE) (reuters.com)
- Zynerba Pharma (ZYNE) Initiates Open-Label Phase 2 Trial of ZYN002 in Developmental and Epileptic Encephalopathies (streetinsider.com)
- Zynerba Pharmaceuticals Initiates Open-Label Phase 2 Trial of ZYN002 in Developmental and Epileptic Encephalopathies (DEE) (markets.financialcontent.com)
Several research analysts have weighed in on ZYNE shares. Cantor Fitzgerald set a $17.00 price objective on Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, January 3rd. Zacks Investment Research upgraded Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a report on Thursday, March 15th. Seaport Global Securities restated a “buy” rating on shares of Zynerba Pharmaceuticals in a report on Tuesday, March 13th. HC Wainwright set a $23.00 price objective on Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, March 13th. Finally, Ladenburg Thalmann began coverage on Zynerba Pharmaceuticals in a report on Monday, January 29th. They issued a “buy” rating and a $25.50 price objective for the company. One analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have given a buy rating to the stock. Zynerba Pharmaceuticals currently has an average rating of “Buy” and an average price target of $17.86.
ZYNE stock opened at $9.15 on Wednesday. The firm has a market capitalization of $119.61, a PE ratio of -3.69 and a beta of 4.92. Zynerba Pharmaceuticals has a 1 year low of $5.42 and a 1 year high of $25.95.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last released its quarterly earnings results on Monday, March 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.60). During the same period in the previous year, the company earned ($0.71) earnings per share. research analysts predict that Zynerba Pharmaceuticals will post -2.63 earnings per share for the current year.
In related news, major shareholder Michael Rapp bought 10,000 shares of the stock in a transaction that occurred on Thursday, March 22nd. The shares were bought at an average cost of $9.28 per share, for a total transaction of $92,800.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 9.91% of the stock is currently owned by insiders.
About Zynerba Pharmaceuticals
Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.